Search Results - "Jan Kosmyna"
-
1
Ethics of HIV cure research: an unfinished agenda
Published in BMC medical ethics (30-06-2021)“…The pursuit of a cure for HIV is a high priority for researchers, funding agencies, governments and people living with HIV (PLWH). To date, over 250 biomedical…”
Get full text
Journal Article -
2
Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus
Published in Clinical infectious diseases (14-08-2023)“…Abstract In this international, multicenter open-label study (ACTG A5379) of HepB-CpG vaccine in people with human immunodeficiency virus (HIV) without prior…”
Get full text
Journal Article -
3
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
Published in Annals of internal medicine (01-05-2023)“…Development of safe and effective SARS-CoV-2 therapeutics is a high priority. Amubarvimab and romlusevimab are noncompeting anti-SARS-CoV-2 monoclonal…”
Get full text
Journal Article -
4
Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection
Published in Annals of internal medicine (01-03-2023)“…Although symptom and viral rebound have been reported after nirmatrelvir-ritonavir treatment, the trajectories of symptoms and viral load during the natural…”
Get full text
Journal Article -
5
Viral and symptom rebound following anti-SARS-CoV-2 monoclonal antibody therapy in a randomized placebo-controlled trial
Published in The Journal of infectious diseases (14-10-2024)“…We explored viral and symptom rebound after COVID-19 amubarvimab/romlusevimab monoclonal antibody therapy vs placebo in the randomized ACTIV-2/A5401 trial…”
Get full text
Journal Article -
6
Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical Trial
Published in The Journal of infectious diseases (15-11-2024)“…Abstract Background We evaluated the fully human polyclonal antibody product SAB-185 in a phase 3 trial for COVID-19. Methods Nonhospitalized high-risk adults…”
Get full text
Journal Article -
7
One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial
Published in Clinical infectious diseases (05-10-2023)“…Abstract Background Camostat inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in vitro. We studied the safety and efficacy of…”
Get full text
Journal Article -
8
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial
Published in Nature microbiology (01-11-2022)“…SARS-CoV-2 mutations that cause resistance to monoclonal antibody (mAb) therapy have been reported. However, it remains unclear whether in vivo emergence of…”
Get full text
Journal Article -
9
LB749. High HBsAb Seroprotection Achieved 4 Weeks after 3 doses of HepB-CpG Vaccine in People Living with HIV (PLWH) without Prior HBV Vaccination (ACTG A5379 Group B Preliminary Results)
Published in Open forum infectious diseases (15-12-2022)“…Abstract Background Three-dose series of conventional alum-adjuvanted Hepatitis B surface antigen (HBsAg)-based vaccines achieve seroprotection rates (SPRs) of…”
Get full text
Journal Article -
10
Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19
Published in JAMA network open (27-10-2022)“…This cohort study of US adults with untreated COVID-19 examines the types and length of symptoms experienced following symptom recurrence…”
Get full text
Journal Article -
11
Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials
Published in JAMA network open (03-04-2023)“…Development of effective, scalable therapeutics for SARS-CoV-2 is a priority. To test the efficacy of combined tixagevimab and cilgavimab monoclonal antibodies…”
Get full text
Journal Article -
12
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trialResearch in context
Published in EClinicalMedicine (01-11-2023)“…Background: With the emergence of SARS-CoV-2 variants resistant to monoclonal antibody therapies and limited global access to therapeutics, the evaluation of…”
Get full text
Journal Article -
13
DEMENTIA AT 700?
Published in The American journal of nursing (01-05-1996)Get full text
Journal Article -
14
Dementia at 700?
Published in The American journal of nursing (01-05-1996)Get full text
Journal Article -
15
Dementia at 700?
Published in The American journal of nursing (01-05-1996)Get full text
Journal Article